Activation, regulation, and inhibition of DYRK1A

被引:159
|
作者
Becker, Walter [1 ]
Sippl, Wolfgang [2 ]
机构
[1] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Fac Med, D-52074 Aachen, Germany
[2] Univ Halle Wittenberg, Inst Pharm, D-4010 Halle, Germany
关键词
CMGC kinases; dual-specificity; DYRK1A; harmine; INDY; kinase inhibitor; structural model; tyrosine autophosphorylation; SYNTHASE KINASE 3-BETA; PROTEIN-KINASE; GLYCOGEN-SYNTHASE; DOWN-SYNDROME; TYROSINE PHOSPHORYLATION; STRUCTURAL BASIS; TRANSCRIPTION FACTOR; INCREASED DOSAGE; AUTOPHOSPHORYLATION; SPECIFICITY;
D O I
10.1111/j.1742-4658.2010.07956.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase with diverse functions in neuronal development and adult brain physiology. Higher than normal levels of DYRK1A are associated with the pathology of neurodegenerative diseases and have been implicated in some neurobiological alterations of Down syndrome, such as mental retardation. It is therefore important to understand the molecular mechanisms that control the activity of DYRK1A. Here we review the current knowledge about the initial self-activation of DYRK1A by tyrosine autophosphorylation and propose that this mechanism presents an ancestral feature of the CMGC group of kinases. However, tyrosine phosphorylation does not appear to regulate the enzymatic activity of DYRK1A. Control of DYRK1A may take place on the level of gene expression, interaction with regulatory proteins and regulated nuclear translocation. Finally, we compare the properties of small molecule inhibitors that target DYRK1A and evaluate their potential application and limitations. The beta-carboline alkaloid harmine is currently the most selective and potent inhibitor of DYRK1A and has proven very useful in cellular assays.
引用
收藏
页码:246 / 256
页数:11
相关论文
共 50 条
  • [41] Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
    Weijun Shen
    Brandon Taylor
    Qihui Jin
    Van Nguyen-Tran
    Shelly Meeusen
    You-Qing Zhang
    Anwesh Kamireddy
    Austin Swafford
    Andrew F. Powers
    John Walker
    John Lamb
    Badry Bursalaya
    Michael DiDonato
    George Harb
    Minhua Qiu
    Christophe M. Filippi
    Lisa Deaton
    Carolina N. Turk
    Wilma L. Suarez-Pinzon
    Yahu Liu
    Xueshi Hao
    Tingting Mo
    Shanshan Yan
    Jing Li
    Ann E. Herman
    Bernhard J. Hering
    Tom Wu
    H. Martin Seidel
    Peter McNamara
    Richard Glynne
    Bryan Laffitte
    Nature Communications, 6
  • [42] Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
    Pozo, Natividad
    Zahonero, Cristina
    Fernandez, Paloma
    Linares, Jose M.
    Ayuso, Angel
    Hagiwara, Masatoshi
    Perez, Angel
    Ricoy, Jose R.
    Hernandez-Lain, Aurelio
    Sepulveda, Juan M.
    Sanchez-Gomez, Pilar
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06): : 2475 - 2487
  • [43] Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits
    Stringer, Megan
    Goodlett, Charles R.
    Roper, Randall J.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2017, 5 (05): : 451 - 465
  • [44] Identification and analysis of a selective DYRK1A inhibitor
    Lin, Tony Eight
    Chao, Min-Wu
    HuangFu, Wei-Chun
    Tu, Huang-Ju
    Peng, Zhao-Xiang
    Su, Chih-Jou
    Sung, Tzu-Ying
    Hsieh, Jui-Hua
    Lee, Cheng-Chung
    Yang, Chia-Ron
    Pan, Shiow-Lin
    Hsu, Kai-Cheng
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [45] Recent research and development of DYRK1A inhibitors
    Zhao, Liyun
    Xiong, Xuan
    Liu, Li
    Liang, Qi
    Tong, Rongsheng
    Feng, Xuanlin
    Bai, Lan
    Shi, Jianyou
    CHINESE CHEMICAL LETTERS, 2022, 33 (04) : 1841 - 1849
  • [46] Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction
    Lan, Cong
    Chen, Caiyu
    Qu, Shuang
    Cao, Nian
    Luo, Hao
    Yu, Cheng
    Wang, Na
    Xue, Yuanzheng
    Xia, Xuewei
    Fan, Chao
    Ren, Hongmei
    Yang, Yongjian
    Jose, Pedro A.
    Xu, Zaicheng
    Wu, Gengze
    Zeng, Chunyu
    EBIOMEDICINE, 2022, 82
  • [47] DYRK1A Kinase Inhibitors with Emphasis on Cancer
    Ionescu, A.
    Dufrasne, F.
    Gelbcke, M.
    Jabin, I.
    Kiss, R.
    Lamoral-Theys, D.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (13) : 1315 - 1329
  • [48] Ocular Phenotype Associated with DYRK1A Variants
    Mejecase, Cecile
    Way, Christopher M.
    Owen, Nicholas
    Moosajee, Mariya
    GENES, 2021, 12 (02) : 1 - 14
  • [49] Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
    Shen, Weijun
    Taylor, Brandon
    Jin, Qihui
    Nguyen-Tran, Van
    Meeusen, Shelly
    Zhang, You-Qing
    Kamireddy, Anwesh
    Swafford, Austin
    Powers, Andrew F.
    Walker, John
    Lamb, John
    Bursalaya, Badry
    DiDonato, Michael
    Harb, George
    Qiu, Minhua
    Filippi, Christophe M.
    Deaton, Lisa
    Turk, Carolina N.
    Suarez-Pinzon, Wilma L.
    Liu, Yahu
    Hao, Xueshi
    Mo, Tingting
    Yan, Shanshan
    Li, Jing
    Herman, Ann E.
    Hering, Bernhard J.
    Wu, Tom
    Seidel, H. Martin
    McNamara, Peter
    Glynne, Richard
    Laffitte, Bryan
    NATURE COMMUNICATIONS, 2015, 6
  • [50] Recent research and development of DYRK1A inhibitors
    Liyun Zhao
    Xuan Xiong
    Li Liu
    Qi Liang
    Rongsheng Tong
    Xuanlin Feng
    Lan Bai
    Jianyou Shi
    ChineseChemicalLetters, 2022, 33 (04) : 1841 - 1849